This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Drug: Navitoclax
Tablet, Oral
Other Name: ABT-263
Drug: Venetoclax
Tablet, Oral
Other Name: Venclexta
Other Name: ABT-199
Other Name: GDC-0199
Dana-Farber Cancer Institute /ID# 206198
Boston, Massachusetts, 02215
ABBVIE CALL CENTER
847.283.8955
abbvieclinicaltrials@abbvie.com
ABBVIE INC.
Study Director
AbbVie